JP2019146574A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019146574A5 JP2019146574A5 JP2019071336A JP2019071336A JP2019146574A5 JP 2019146574 A5 JP2019146574 A5 JP 2019146574A5 JP 2019071336 A JP2019071336 A JP 2019071336A JP 2019071336 A JP2019071336 A JP 2019071336A JP 2019146574 A5 JP2019146574 A5 JP 2019146574A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- hiv
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15200138.4 | 2015-12-15 | ||
| EP15200138 | 2015-12-15 | ||
| EP16194124 | 2016-10-17 | ||
| EP16194124.0 | 2016-10-17 | ||
| JP2018531537A JP6510149B2 (ja) | 2015-12-15 | 2016-12-15 | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531537A Division JP6510149B2 (ja) | 2015-12-15 | 2016-12-15 | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019146574A JP2019146574A (ja) | 2019-09-05 |
| JP2019146574A5 true JP2019146574A5 (enExample) | 2020-02-06 |
| JP6959289B2 JP6959289B2 (ja) | 2021-11-02 |
Family
ID=57737697
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531537A Active JP6510149B2 (ja) | 2015-12-15 | 2016-12-15 | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
| JP2019071336A Expired - Fee Related JP6959289B2 (ja) | 2015-12-15 | 2019-04-03 | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531537A Active JP6510149B2 (ja) | 2015-12-15 | 2016-12-15 | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US10369214B2 (enExample) |
| EP (3) | EP3584252B1 (enExample) |
| JP (2) | JP6510149B2 (enExample) |
| KR (1) | KR20180086207A (enExample) |
| CN (2) | CN108368157B (enExample) |
| AU (2) | AU2016369326B2 (enExample) |
| BR (1) | BR112018011122A2 (enExample) |
| CA (1) | CA3008542C (enExample) |
| CY (2) | CY1122705T1 (enExample) |
| DK (2) | DK3584252T3 (enExample) |
| EA (1) | EA038974B1 (enExample) |
| ES (2) | ES2898271T3 (enExample) |
| HR (2) | HRP20191902T1 (enExample) |
| HU (2) | HUE055916T2 (enExample) |
| IL (1) | IL259942B2 (enExample) |
| LT (2) | LT3584252T (enExample) |
| MA (3) | MA44059B1 (enExample) |
| MD (2) | MD3390430T2 (enExample) |
| ME (1) | ME03545B (enExample) |
| MX (2) | MX383507B (enExample) |
| PH (1) | PH12018501047A1 (enExample) |
| PL (2) | PL3584252T3 (enExample) |
| PT (1) | PT3390430T (enExample) |
| RS (2) | RS62360B1 (enExample) |
| SG (2) | SG10202109457RA (enExample) |
| SI (2) | SI3390430T1 (enExample) |
| SM (2) | SMT202100623T1 (enExample) |
| TW (2) | TWI707039B (enExample) |
| WO (1) | WO2017102929A1 (enExample) |
| ZA (1) | ZA201803978B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2961024A1 (en) | 2014-09-26 | 2016-03-31 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for inducing protective immunity against human immunodeficiency virus infection |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| EP3031923A1 (en) * | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentiviral vector-based japanese encephalitis immunogenic composition |
| CA3008542C (en) | 2015-12-15 | 2020-06-02 | Janssen Vaccines & Prevention B.V. | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof |
| JP6595132B2 (ja) | 2016-06-16 | 2019-10-23 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Ｈｉｖワクチン製剤 |
| CN110494159A (zh) | 2016-09-02 | 2019-11-22 | 扬森疫苗与预防公司 | 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法 |
| SG10202001956UA (en) | 2016-09-15 | 2020-04-29 | Janssen Vaccines & Prevention Bv | Trimer stabilizing hiv envelope protein mutations |
| EP3638302B1 (en) * | 2017-06-15 | 2024-03-13 | Janssen Vaccines & Prevention B.V. | Poxvirus vectors encoding hiv antigens, and methods of use thereof |
| MY200554A (en) | 2017-07-19 | 2024-01-03 | Janssen Vaccines & Prevention Bv | Trimer stabilizing hiv envelope protein mutations |
| WO2019055888A1 (en) | 2017-09-18 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT |
| CA3077340A1 (en) * | 2017-11-17 | 2019-05-23 | Grifols Diagnostic Solutions Inc. | Novel mammalian expressed human immunodeficiency virus envelope protein antigens |
| WO2020214203A1 (en) * | 2019-04-17 | 2020-10-22 | The Wistar Institute | Replication deficient adenoviral vectors for hiv vaccine applications |
| WO2020237052A1 (en) | 2019-05-22 | 2020-11-26 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| AU2020381082B2 (en) | 2019-11-07 | 2022-09-22 | Janssen Vaccines & Prevention B.V. | Protein purification |
| CA3182703A1 (en) | 2020-05-12 | 2021-11-18 | Janssen Vaccines & Prevention B.V. | Administration of homologous adenoviral vectors |
| WO2021249011A1 (en) * | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Hiv vaccine compositions, methods, and uses thereof |
| WO2022006095A2 (en) * | 2020-06-29 | 2022-01-06 | Duke University | Mosaic hiv-1 envelopes to induce adcc responses |
| US20220118081A1 (en) | 2020-10-20 | 2022-04-21 | Janssen Vaccines & Prevention B.V. | HIV vaccine regimens |
| CN116867517A (zh) | 2021-02-23 | 2023-10-10 | 扬森疫苗与预防公司 | 三聚体稳定性hiv包膜蛋白突变 |
| US20230000973A1 (en) * | 2021-06-25 | 2023-01-05 | Janssen Vaccines & Prevention B.V. | Combinations of Vaccines and Neutralizing Antibodies for Treating Human Immunodeficiency Virus Infection in Subjects Undergoing Antiretroviral Treatment |
| WO2023242155A1 (en) | 2022-06-14 | 2023-12-21 | Janssen Vaccines & Prevention B.V. | Compositions and methods for the diagnosis of hiv infection |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
| WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| US5761893A (en) | 1996-10-22 | 1998-06-09 | Lofquist Welding, Inc. | Crop saving attachment for the snouts of combines |
| EP1816204B1 (en) | 1999-05-17 | 2010-10-20 | Crucell Holland B.V. | Recombinant Adenovirus of the Ad26 serotype |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6710173B1 (en) | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
| CA2384271A1 (en) | 1999-09-17 | 2001-03-22 | Joseph G. Sodroski | Stabilized soluble glycoprotein trimers |
| DE20122302U1 (de) | 2000-11-23 | 2005-02-24 | Bavarian Nordic A/S | Variante des Modifizierten Vaccinia-Ankara-Virus |
| CA2785699A1 (en) * | 2001-07-05 | 2003-01-16 | Novartis Vaccines And Diagnostics, Inc. | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| JP4302513B2 (ja) * | 2001-07-05 | 2009-07-29 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 抗原性ｂ型ｈｉｖポリペプチドおよび／または抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用 |
| AU2002356690B2 (en) | 2001-12-04 | 2008-07-24 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
| ES2335657T3 (es) | 2002-04-25 | 2010-03-31 | Crucell Holland B.V. | Medios y metodos para la produccion de vectores de adenovirus. |
| WO2004001032A2 (en) | 2002-04-25 | 2003-12-31 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
| WO2004044155A2 (en) | 2002-11-07 | 2004-05-27 | Beth Israel Deaconess Medical Center | MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE |
| EP1578766B1 (en) | 2002-12-03 | 2013-02-13 | University of Massachusetts | Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods |
| EP2359851A3 (en) | 2003-03-28 | 2011-08-31 | The Government of the United States of America, represented by The Secretary, Department of Health and Human Services | MVA expressing modified hiv envelope, gag, and pol genes |
| EP1667631A4 (en) | 2003-09-15 | 2010-04-14 | Novartis Vaccines & Diagnostic | COMBINATION PATHS FOR GENERATING IMMUNE RESPONSES |
| US20070298051A1 (en) | 2003-11-19 | 2007-12-27 | Beth Israel Deaconess Medical Center | Adjuvants Of Immune Response |
| ES2871907T3 (es) | 2004-01-23 | 2021-11-02 | Msd Italia Srl | Portadores de vacuna de adenovirus de chimpancé |
| EP1737885A2 (en) * | 2004-04-12 | 2007-01-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method of using adenoviral vectors to induce an immune response |
| US20080274134A1 (en) | 2004-06-15 | 2008-11-06 | Norbert Schulke | Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex |
| AU2005274948B2 (en) * | 2004-07-16 | 2011-09-22 | Genvec, Inc. | Vaccines against aids comprising CMV/R-nucleic acid constructs |
| ES2539010T3 (es) * | 2004-08-27 | 2015-06-25 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Virus MVA recombinantes que expresan genes env, gag y pol modificados de VIH clado A/G, clado B, y clado C |
| US7741099B2 (en) | 2004-10-13 | 2010-06-22 | Beth Israel Deaconess Medical Center Inc. | Adenoviral vectors and uses thereof |
| CN101588813A (zh) * | 2005-04-12 | 2009-11-25 | 杜克大学 | 诱导人类免疫缺陷病毒的中和抗体的方法 |
| US20100221241A1 (en) | 2005-07-06 | 2010-09-02 | University Of Maryland Biotechnology Institute | Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites |
| AU2006283101B2 (en) | 2005-08-23 | 2013-03-07 | Beth Israel Deaconess Medical Center | Polyvalent vaccine |
| WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| WO2007149491A2 (en) | 2006-06-19 | 2007-12-27 | Progenics Pharmaceuticals, Inc. | Soluble stabilized trimeric hiv env proteins and uses thereof |
| CA2667358A1 (en) | 2006-10-23 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof |
| WO2008140579A2 (en) | 2006-11-17 | 2008-11-20 | New York University | Induction of broadly reactive neutralizing antibodies by focusing the immune response on v3 epitopes of the hiv-1 gp120 envelope |
| HUE031411T2 (en) | 2007-03-02 | 2017-07-28 | Glaxosmithkline Biologicals Sa | New Methods and Preparations |
| SMT202000101T1 (it) | 2008-10-10 | 2020-03-13 | Childrens Medical Center | Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente |
| PT2358757T (pt) * | 2008-11-18 | 2018-12-04 | Beth Israel Deaconess Medical Ct Inc | Vacinas antivirais com imunogenicidade celular melhorada |
| WO2010085984A1 (en) | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| MX2011007980A (es) | 2009-02-02 | 2011-08-17 | Okairos Ag | Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas. |
| WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
| CN105399833B (zh) | 2010-01-04 | 2019-09-06 | Kj 生物科学有限公司 | 用于疫苗和诊断学的Dps融合蛋白 |
| US8859257B2 (en) | 2010-01-28 | 2014-10-14 | Bavarian Nordic A/S | Vaccinia virus mutants containing the major genomic deletions of MVA |
| EP2611465A4 (en) | 2010-08-31 | 2014-06-04 | Theraclone Sciences Inc | ANTIBODIES FOR NEUTRALIZING THE HUMAN IMMUNODICITY VIRUS (HIV) |
| CN103370411B (zh) | 2010-12-14 | 2016-05-04 | 美国卫生和人类服务部 | 腺病毒血清型26和血清型35线状病毒疫苗 |
| KR102007444B1 (ko) * | 2011-04-25 | 2019-08-06 | 어드밴스드 바이오사이언스 라보라토리즈, 인코포레이티드 | 절단형 hiv 피막 단백질(env), 이와 관련된 방법 및 조성물 |
| WO2013036791A2 (en) | 2011-09-09 | 2013-03-14 | Beth Israel Deaconess Medical Center, Inc. | Modified adenoviral vectors and methods of treatment using same |
| EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| WO2013040766A1 (zh) * | 2011-09-21 | 2013-03-28 | 中国疾病预防控制中心性病艾滋病预防控制中心 | 可诱导针对hiv的广谱免疫应答的方法和疫苗 |
| WO2013055908A1 (en) | 2011-10-12 | 2013-04-18 | The Scripps Research Institute | An hiv-1 gp120 mini v3 loop and uses thereof |
| US9683268B2 (en) | 2012-09-19 | 2017-06-20 | Beth Israel Deaconess | Viruses associated with immunodeficiency and enteropathy and methods using same |
| CN105051198A (zh) | 2012-11-16 | 2015-11-11 | 貝丝以色列女执事医疗中心 | 重组腺病毒及其用途 |
| CN105263506B (zh) | 2013-01-07 | 2018-03-09 | 贝丝以色列女执事医疗中心 | 稳定的人免疫缺陷病毒(HIV)包膜(EnV)三聚体疫苗及其使用方法 |
| WO2014124301A1 (en) | 2013-02-07 | 2014-08-14 | University Of Washington Through Its Center For Commercialization | Self-assembling protein nanostructures |
| US9624510B2 (en) * | 2013-03-01 | 2017-04-18 | The Wistar Institute | Adenoviral vectors comprising partial deletions of E3 |
| US10376583B2 (en) | 2013-09-30 | 2019-08-13 | Beth Israel Deaconess Medical Center, Inc. | Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator |
| EP3052518B1 (en) * | 2013-10-04 | 2020-01-08 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (hiv) clade c envelope (env) trimer vaccines and methods of using same |
| WO2015128421A1 (en) * | 2014-02-28 | 2015-09-03 | Crucell Holland B.V. | Replicating recombinant adenovirus vectors, compositions, and methods of use thereof |
| US10400015B2 (en) | 2014-09-04 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant HIV-1 envelope proteins and their use |
| CA2961024A1 (en) | 2014-09-26 | 2016-03-31 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for inducing protective immunity against human immunodeficiency virus infection |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| ES2836432T3 (es) * | 2015-03-18 | 2021-06-25 | Janssen Vaccines & Prevention Bv | Ensayos para sistemas de expresión recombinante |
| CA3008542C (en) | 2015-12-15 | 2020-06-02 | Janssen Vaccines & Prevention B.V. | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof |
| JP6595132B2 (ja) | 2016-06-16 | 2019-10-23 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Ｈｉｖワクチン製剤 |
| CN110494159A (zh) | 2016-09-02 | 2019-11-22 | 扬森疫苗与预防公司 | 在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法 |
| SG10202001956UA (en) | 2016-09-15 | 2020-04-29 | Janssen Vaccines & Prevention Bv | Trimer stabilizing hiv envelope protein mutations |
| DE102018124348A1 (de) | 2018-10-02 | 2020-04-02 | Haver & Boecker Ohg | Füllkasten und Verfahren zum Füllen von Gebinden |
-
2016
- 2016-12-15 CA CA3008542A patent/CA3008542C/en active Active
- 2016-12-15 TW TW105141650A patent/TWI707039B/zh not_active IP Right Cessation
- 2016-12-15 MA MA44059A patent/MA44059B1/fr unknown
- 2016-12-15 EP EP19186284.6A patent/EP3584252B1/en active Active
- 2016-12-15 MD MDE20181009T patent/MD3390430T2/ro not_active IP Right Cessation
- 2016-12-15 IL IL259942A patent/IL259942B2/en unknown
- 2016-12-15 RS RS20211171A patent/RS62360B1/sr unknown
- 2016-12-15 SG SG10202109457R patent/SG10202109457RA/en unknown
- 2016-12-15 SM SM20210623T patent/SMT202100623T1/it unknown
- 2016-12-15 KR KR1020187016460A patent/KR20180086207A/ko active Pending
- 2016-12-15 HR HRP20191902TT patent/HRP20191902T1/hr unknown
- 2016-12-15 PL PL19186284T patent/PL3584252T3/pl unknown
- 2016-12-15 DK DK19186284.6T patent/DK3584252T3/da active
- 2016-12-15 MX MX2018007198A patent/MX383507B/es unknown
- 2016-12-15 HR HRP20211566TT patent/HRP20211566T1/hr unknown
- 2016-12-15 TW TW109138473A patent/TWI792091B/zh not_active IP Right Cessation
- 2016-12-15 MD MDE20200025T patent/MD3584252T2/ro not_active IP Right Cessation
- 2016-12-15 EP EP21185351.0A patent/EP3964569A1/en not_active Withdrawn
- 2016-12-15 PL PL16822410T patent/PL3390430T3/pl unknown
- 2016-12-15 ES ES19186284T patent/ES2898271T3/es active Active
- 2016-12-15 SM SM20190629T patent/SMT201900629T1/it unknown
- 2016-12-15 HU HUE19186284A patent/HUE055916T2/hu unknown
- 2016-12-15 EP EP16822410.3A patent/EP3390430B1/en active Active
- 2016-12-15 AU AU2016369326A patent/AU2016369326B2/en active Active
- 2016-12-15 MA MA47522A patent/MA47522B1/fr unknown
- 2016-12-15 MA MA055825A patent/MA55825A/fr unknown
- 2016-12-15 CN CN201680073839.5A patent/CN108368157B/zh active Active
- 2016-12-15 ME MEP-2019-304A patent/ME03545B/me unknown
- 2016-12-15 SG SG11201804411TA patent/SG11201804411TA/en unknown
- 2016-12-15 PT PT168224103T patent/PT3390430T/pt unknown
- 2016-12-15 US US15/380,123 patent/US10369214B2/en active Active
- 2016-12-15 DK DK16822410T patent/DK3390430T3/da active
- 2016-12-15 ES ES16822410T patent/ES2753854T3/es active Active
- 2016-12-15 RS RSP20191399 patent/RS59447B1/sr unknown
- 2016-12-15 SI SI201630480T patent/SI3390430T1/sl unknown
- 2016-12-15 WO PCT/EP2016/081159 patent/WO2017102929A1/en not_active Ceased
- 2016-12-15 EA EA201891415A patent/EA038974B1/ru unknown
- 2016-12-15 JP JP2018531537A patent/JP6510149B2/ja active Active
- 2016-12-15 BR BR112018011122-8A patent/BR112018011122A2/pt active Search and Examination
- 2016-12-15 CN CN202210312432.0A patent/CN114686495A/zh active Pending
- 2016-12-15 LT LTEP19186284.6T patent/LT3584252T/lt unknown
- 2016-12-15 HU HUE16822410A patent/HUE045993T2/hu unknown
- 2016-12-15 LT LT16822410T patent/LT3390430T/lt unknown
- 2016-12-15 SI SI201631333T patent/SI3584252T1/sl unknown
-
2018
- 2018-05-16 PH PH12018501047A patent/PH12018501047A1/en unknown
- 2018-06-13 MX MX2021006931A patent/MX2021006931A/es unknown
- 2018-06-14 ZA ZA2018/03978A patent/ZA201803978B/en unknown
-
2019
- 2019-04-03 JP JP2019071336A patent/JP6959289B2/ja not_active Expired - Fee Related
- 2019-05-17 AU AU2019203468A patent/AU2019203468B2/en not_active Ceased
- 2019-06-13 US US16/440,463 patent/US10973907B2/en active Active
- 2019-11-13 CY CY20191101197T patent/CY1122705T1/el unknown
-
2021
- 2021-03-03 US US17/190,569 patent/US11896663B2/en active Active
- 2021-10-19 CY CY20211100901T patent/CY1125387T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019146574A5 (enExample) | ||
| HRP20211566T1 (hr) | Antigeni, vektori, pripravci virusa humane imunodeficijencije i postupci njihove uporabe | |
| Kinney et al. | Nucleotide sequence of the 26 S mRNA of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and deduced sequence of the encoded structural proteins | |
| JP6749357B2 (ja) | Ｈｉｖワクチン接種のための免疫原 | |
| US8389275B2 (en) | Fusion proteins of HIV regulatory/accessory proteins | |
| CN110958887B (zh) | 编码hiv抗原的痘病毒载体及其使用方法 | |
| KR20120083899A (ko) | 마이코박테리아 백신들 | |
| JP2019527055A5 (enExample) | ||
| RU2015155821A (ru) | Вакцины против малярии | |
| WO2014205579A4 (en) | Modified matrix proteins of vesicular stomatitis virus | |
| JP2006523224A (ja) | 免疫原性組成物および方法 | |
| JP2019214579A5 (enExample) | ||
| Malkevitch et al. | A call for replicating vector prime-protein boost strategies in HIV vaccine design | |
| ZA200504021B (en) | Methods and compositions for immunization against HIV | |
| WO2019123250A1 (en) | Methods and compositions for inducing an immune response against hepatitis b virus (hbv) | |
| JP6612237B2 (ja) | ヒトｔリンパ向性ウイルス１型に対する免疫応答を生成するためのレンチウイルスベクター | |
| AU2020279988A1 (en) | Dosage regimens for vaccines | |
| Hara et al. | Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors | |
| Bongard et al. | Interference of retroviral envelope with vaccine-induced CD8+ T cell responses is relieved by co-administration of cytokine-encoding vectors | |
| Bayer et al. | Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes | |
| Chen et al. | Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses | |
| WO2023092023A2 (en) | Methods of preventing, treating, or reducing the severity of coronavirus disease 2019 (covid-19) | |
| JP5635950B2 (ja) | 免疫原性組成物および方法 | |
| Huisman et al. | Evaluation of ISCOM-adjuvanted subunit vaccines containing recombinant feline immunodeficiency virus Rev, OrfA and envelope protein in cats |